KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Net Income: 2009-2025

Historic Net Income for Biomarin Pharmaceutical (BMRN) over the last 14 years, with Sep 2025 value amounting to -$30.7 million.

  • Biomarin Pharmaceutical's Net Income fell 128.98% to -$30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $520.4 million, marking a year-over-year increase of 61.47%. This contributed to the annual value of $426.9 million for FY2024, which is 154.62% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Net Income stood at -$30.7 million for Q3 2025, which was down 112.78% from $240.5 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Net Income registered a high of $240.5 million during Q2 2025, and its lowest value of -$57.9 million during Q4 2021.
  • Over the past 3 years, Biomarin Pharmaceutical's median Net Income value was $88.7 million (recorded in 2024), while the average stood at $90.0 million.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Net Income crashed by 440.02% in 2021 and then spiked by 8,282.73% in 2023.
  • Biomarin Pharmaceutical's Net Income (Quarterly) stood at -$57.9 million in 2021, then soared by 99.57% to -$249,000 in 2022, then spiked by 8,282.73% to $20.4 million in 2023, then surged by 513.22% to $124.9 million in 2024, then tumbled by 128.98% to -$30.7 million in 2025.
  • Its Net Income stands at -$30.7 million for Q3 2025, versus $240.5 million for Q2 2025 and $185.7 million for Q1 2025.